Disposals of own shares

Brussels (Belgium), 28 January 2022 – 20:00 (CET) – regulated information

Disposal of own shares

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long-Term Incentive Program of the UCB Group, as follows:

This press release is available on UCB SA/NV’s website via the following link.

Investor Relations

Antje Witte          

Investor Relations, UCB

T +32.2.559.94.14 antje.witte@ucb.com

Corporate Communications

Laurent Schots 

Media Relations, UCB  

T+32.2.559.92.64  Laurent.schots@ucb.com 

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news